Johnson & Johnson's Stelara shows promise against lupus in study
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
San Diego
JOHNSON & Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a mid-stage clinical trial, according to data released on Saturday.
Stelara, a biotech drug known chemically as ustekinumab, is already approved for psoriasis, psoriatic arthritis and Crohn's disease and had third-quarter sales of US$1.12 billion.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
